Patent · US Active

Antibodies against ErbB3 and uses thereof

US7846440B2 · kind B2 · utility

52Cited by

8References

18Claims

0Family size

Assignee

Merrimack Pharmaceuticals, Inc. · US

Inventors

Birgit Schoeberl · Cambridge, US
Ulrik Nielsen · Quincy, US
Michael Feldhaus · Lebanon, US
Arumugam Muruganandam · Bengaluru, IN
David Buckler · Mount Olive, US

Key dates

Filing date	Feb 15, 2008
Grant date	Dec 7, 2010
Priority date	—
Expiry date	Feb 15, 2028

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. In a particular embodiment, the antibodies are capable of binding to ErbB3 and inhibiting ligand mediated phosphorylation of the receptor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.